Houston, TX (PRWEB) March 29, 2008
TradeRXchange.com will provide an utterly unique resource for those trading in the life-science sector. Our objective is not only to improve your bottom line, but to give you piece of mind in your investment decisions. The e-journal is in its formative stage currently, and is freely acceptable. However, as the content blue-print is realized, it will become a competitive tool in any investor's repartee.
Already featured in its first week, an exclusive interview with Dr. Kohkan Shamsi, CEO of Acunova. Acunova is a Contract Research Organization (CRO), in India's emerging tech sector. Also, our March journal watch shed some light on the fate of Aspect Medical's white knight - the BIS monitor. Coming soon, a journal watch you can't afford to miss and finally, the watchlist. TradeRXchange.com has been monitoring its watchlist for approximately two years. One of its featured equities, Encysive Pharmaceuticals, recently purchased by Pfizer for over 200% of its share value. This was anticipated by our research team reviewing the content and status of its pipeline, which as Pfizer's analysts agreed, has great upside potential. TradeRXchange.com is building its upside portfolio right now, please visit the website and contact us with questions and comments.
http://www.TradeRXchange.com is staffed exclusively by M.D's, PhD's, and MBA's. It will offer everything including interviews with business and clinical leaders, comprehensive surveillance of Medical Journals and Clinical Trial information, as well as telephonic consultation on specific healthcare products and services.